AZTR (Azitra, Inc.) מחיר לרווח עתידי

The US dermatology sector operates in a neutral environment free from sanction threats. Azitra, Inc. (AZTR) is implementing advanced bacterial engineering to combat severe dermatoses, while the use of live microbiomes ensures patent protection and high therapy costs. The issuer's forward P/E reflects market expectations, with the current parameter equal to 0.00, which helps assess the fairness of the capitalization relative to future earnings.

This indicator is calculated as the ratio of current market capitalization to expected net income, measuring the market's willingness to pay a premium for future business growth rates. By analyzing the forward P/E ratio of Azitra, Inc. (AZTR), an investor assesses the extent to which the success of ATR-12 therapy and FDA approval are priced into the stock to timely recognize the risk of asset overvaluation should clinical progress slow.